8-K: MyMD Pharmaceuticals Rebrands as TNF Pharmaceuticals, Ticker Symbol Changes to TNFA

MyMD Pharmaceuticals has rebranded to TNF Pharmaceuticals, reflecting its focus on TNF-alpha inhibition, and its stock will now trade under the ticker symbol TNFA.

Summary

• MyMD Pharmaceuticals, Inc. has officially changed its name to TNF Pharmaceuticals, Inc., effective July 22, 2024.
• The company's stock ticker symbol has changed from MYMD to TNFA, effective before the market open on July 24, 2024.
• The name change reflects the company's focus on TNF-alpha, a protein involved in inflammation and autoimmunity.
• The company's lead drug candidate, MYMD-1, is a TNF-alpha inhibitor being developed for various inflammatory conditions.
• A successful Phase 2 study of MYMD-1 for sarcopenia was completed in 2023, and mid-stage clinical trials are planned.
• The company is also developing Supera-CBD, a synthetic derivative of cannabidiol, for chronic pain, addiction, and epilepsy.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the rebranding and focus on a promising drug candidate, MYMD-1, but also includes standard risk disclosures.

Positives

• The rebranding to TNF Pharmaceuticals aligns the company's name with its scientific focus on TNF-alpha.
• The new ticker symbol, TNFA, is more representative of the company's therapeutic focus.
• MYMD-1 is a first-in-class oral treatment for reducing TNF-alpha and inflammation.
• The company has completed a successful Phase 2 study for MYMD-1 in sarcopenia.
• The company has a second drug platform, Supera-CBD, targeting chronic pain, addiction, and epilepsy.

Risks

• The company's ability to maintain compliance with Nasdaq listing standards is a risk.
• There are risks associated with obtaining and maintaining regulatory approvals for clinical trials.
• The timing and results of planned clinical trials are uncertain.
• The company's ability to secure sufficient funding for its pharmaceutical candidates is a risk.
• Increased competition in the pharmaceutical market is a potential risk.
• Changes in political, economic, or regulatory conditions could impact the company.
• The company's ability to retain key employees is a risk.
• The company's ability to protect its intellectual property is a risk.

Future Outlook

The company plans to move forward with mid-stage clinical trials of MYMD-1 in sarcopenia and is also developing Supera-CBD for chronic pain, addiction, and epilepsy. The company is focused on developing novel therapies that treat the causes of disease rather than just the symptoms.

Management Comments

• Our new name, TNF Pharmaceuticals, is more closely aligned with our scientific focus on TNF-alpha, said the Company's President and Chief Medical Officer Mitchell Glass, M.D.
• Our Companys new name and stock identity comes at an important time in our clinical development of MYMD-1, illuminating both our core science and our clinical candidates strong potential to be the first TNFinhibitor in this indication, said the Companys President, Chief Medical Officer and Director, Mitchell Glass, M.D.

Industry Context

The rebranding and focus on TNF-alpha inhibition aligns with the growing interest in therapies targeting inflammatory and autoimmune diseases. The development of an oral TNF-alpha inhibitor could be a significant advancement in the field, as current treatments are primarily administered through infusion or injection.

Comparison to Industry Standards

• The company's lead drug candidate, MYMD-1, is positioned as a novel, orally dosed TNF-alpha inhibitor, which differentiates it from existing TNF-alpha blockers that are typically administered via infusion or injection.
• Companies like AbbVie (Humira), Amgen (Enbrel), and Johnson & Johnson (Remicade) have established TNF-alpha inhibitors as effective treatments for various inflammatory conditions, but these are not orally administered.
• The successful Phase 2 study of MYMD-1 in sarcopenia is a positive step, but further clinical trials are needed to confirm its efficacy and safety compared to other treatments in development for sarcopenia and related conditions.

Stakeholder Impact

• Shareholders will see a change in the company's name and ticker symbol.
• The rebranding may improve the company's image and attract new investors.
• The development of new therapies could benefit patients with age-related diseases and autoimmune conditions.
• The company's employees will be working under a new company name.

Next Steps

• The company will proceed with mid-stage clinical trials of MYMD-1.
• The company will continue development of Supera-CBD.
• The company will report all stock trading, SEC filings, and market-related information under the new ticker symbol TNFA.

Key Dates

Keywords

TNF Pharmaceuticals, MyMD Pharmaceuticals, TNFA, MYMD, TNF-alpha, MYMD-1, sarcopenia, Supera-CBD, clinical trials, biopharmaceutical, inflammation, autoimmune, immuno-metabolic